| Name | Shares allotted | % of global offering | % of post-IPO shares | Lock-up |
|---|---|---|---|---|
| 联影医疗科技香港有限公司 | 0 | 4.50% | — | 6 months |
| 中国新锐医药控股有限公司 | 0 | 4.50% | — | 6 months |
| 卓投企业管理(香港)有限公司 | 0 | 35.98% | — | 6 months |
| Rank | % of international placing | % of global offering |
|---|---|---|
| 前1名 | — | — |
The 336x oversubscription ratio reflects intense retail enthusiasm for this healthcare AI offering, likely bolstered by clawback reallocation that boosted the public tranche. A hit rate of 30.3% is relatively generous for such demand, allowing many small investors to obtain partial lots. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
A notable tier anomaly exists: the A-tail tier (250,000 shares) expects 0.6154 lots, nearly matching the B-head tier (300,000 shares, 0.7023 lots), indicating marginal allocation gain for a 20% larger application. This compression suggests poor broker fee efficiency for those barely entering margin financing, as the incremental capital yields minimal extra shares. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Mainland Chinese applicants comprised 78.3% of the holder base, signaling strong domestic demand and brand recognition for the company. The gender split is virtually even (49.8% male), and the average investor age of 46 points to a mature, experienced demographic. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
This page shows allotment analysis for Rimag Group (02522): one-lot hit rate, Pool A/B allotment distribution, oversubscription multiple, and grey-market and first-day performance. Data is parsed from the HKEX allotment results announcement. How allotment rates and clawback work is explained in How Hong Kong IPO Allotment Rates Work.

